ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2655

Rapid and Effective Response to Immunosuppression in Treating Macrophage Activation Syndrome Associated with a Heterozygous Dominant Negative Mutation in RAB27a Leading to Decreased Cytolytic Activity

Randy Q. Cron1, Mingce Zhang2, Christina J. Bemrich-Stolz2 and Timothy Beukelman1, 1Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 2Pediatrics, Univ of Alabama-Birmingham, Birmingham, AL

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Anakinra, corticosteroids, cyclosporine, macrophage activation syndrome and natural killer (NK) cells

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Pediatric Rheumatology - Pathogenesis and Genetics

Session Type: Abstract Submissions (ACR)

Background/Purpose: Hemophagocytic lymphohistiocytosis (HLH) is an often fatal disorder of infancy resulting from homozygous mutations in proteins involved in cytolysis (e.g. MUNC13-4, RAB27a, Perforin 1, Syntaxin11, STXBP2). HLH treatment is an etoposide based aggressive chemotherapy, and associated mortality remains problematic. Secondary forms of HLH, or macrophage activation syndrome (MAS), frequently result beyond infancy from rheumatologic, infectious, and oncologic conditions. MAS is typically treated with immunosuppression, including high dose Corticosteroids, Cyclosporine, and, recently, the IL-1 receptor antagonist, Anakinra (CCA). Of late, mutations in HLH associated cytolytic pathway genes have been identified in children with MAS. The importance of these mutations in the pathophysiology of MAS, and the appropriate treatment for MAS in these settings remains unclear. 

Methods: Chart review was performed for a teen with MAS successfully treated with CCA. Cytolytic activity of a natural killer (NK) cell line was assessed following over-expression of a RAB27a mutant protein identified in this girl. Lentiviral expression vectors were generated with the RAB27a mutation, and a wild-type RAB27a sequence control, sequenced for authenticity, and introduced into the NK-92 human NK cell line by transduction. Transduced NK cells were analyzed for transgene expression by co-expression of green fluorescence protein, and tested for their ability to lyse calcein violet loaded K562 NK target cells at varying effector to target cell ratios.

Results: An 18-year-old girl presented with 2 weeks of fever (>102oF) and abdominal pain. Exam revealed a febrile, semi-coherent female with hepatosplenomegaly. Extensive infectious, oncologic, and rheumatic diseases work-ups were negative. Laboratory findings revealed pancytopenia; severe hepatitis; coagulopathy; elevated ferritin, triglycerides, soluble CD25, and soluble CD163; increased CD163 staining of bone marrow; markedly decreased NK cell function; ESR of 10 mm/hr. Sequencing of HLH genes revealed a single copy RAB27a mutation (259 G>A, A87P) known to be associated with type II Griscelli syndrome/HLH. She met 8 of 8 HLH criteria and was treated for MAS with CCA. She markedly and rapidly clinically improved. Her ferritin fell from 8,446 to 201 ng/ml (<115), and her AST fell from 4,639 U/L to 176 U/L, within 4 days of CCA. Lentiviral transduction of wild-type RAB27a into the NK-92 cell line had no effect on cytolysis of K562 target cells in vitro, whereas over-expression of the 259 G>A patient mutation decreased cytolytic activity by ~50%.

Conclusion: The distinction between HLH and MAS is becoming blurred as mutations in HLH genes are identified in patients with MAS. Perhaps later age of onset reflects heterozygous versus homozygous defects in cytolytic pathway proteins. Our data suggests single gene copy mutations can partially disrupt cytolytic activity through a dominant negative effect. Important treatment differences exist between protocols for HLH and MAS, and our patient’s response to CCA immunosuppression suggests HLH associated genetic mutations presenting later in life may be responsive to less aggressive/toxic (non-chemotherapeutic) immunosuppression.


Disclosure:

R. Q. Cron,

Genentech and Biogen IDEC Inc.,

5,

Novartis Pharmaceutical Corporation,

5;

M. Zhang,
None;

C. J. Bemrich-Stolz,
None;

T. Beukelman,

Novartis Pharmaceutical Corporation,

5.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/rapid-and-effective-response-to-immunosuppression-in-treating-macrophage-activation-syndrome-associated-with-a-heterozygous-dominant-negative-mutation-in-rab27a-leading-to-decreased-cytolytic-activity/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology